All In MedTech

FDA Clearance Tracker · P150038-S015

Exablate Model 4000 Type 1.0 and 1.1 Systems (“Exablate Neuro”)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 18, 2023

Approved

Time to decision

767 days

Received Jun 11, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P150038-S015
Device name
Exablate Model 4000 Type 1.0 and 1.1 Systems (“Exablate Neuro”)
Applicant
Insightec
Applicant location
Tirat Carmel
Received
Jun 11, 2021
Decided
Jul 18, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P150038

Device type

Device class
Class III

Every decision under product code POH

FDA's approval statement

As written in FDA's record.

Approval for a change to the prescribers labeling to include the post-approval study (PAS) results from the 5-year follow-up.

Source documents

Other decisions for Insightec

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.